Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease

Journal of Renal Nutrition

Volumn 11, Issue 2, 2001, Pages 67-72

  Dierkes, Jutta ^a   Domröse, Ute ^b   Bosselmann, Klaus Peter ^b   Neumann, Klaus Hinrich ^b   Luley, Claus ^a  

^a Institute of Clinical Chemistry   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PYRIDOXINE; RENAL DIALYSIS; VITAMIN B 12;

EID: 0035321614     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/jren.2001.22484     Document Type: Article

References (27)

1. Kark JD, Selhub J, Adler B, et al: Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med 131:321-330, 1999
2. Nygard O, Nordrehaug JE, Refsum H, et al: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236, 1997
3. Hoogeveen EK, Kostense PJ, Jakobs C, et al: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 101:1506-1511, 2000
4. Hankey GJ, Eikelboom JW: Homocysteine and vascular disease. Lancet 354:407-413, 1999
5. Bostom AG, Shemin D, Lapane KL, et al: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 114:93-103, 1995
6. Dierkes J, Domrose U, Ambrosch A, et al: Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 51:108-115, 1999
7. Moustapha A, Gupta A, Robinson K, et al: Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 55:1470-1475, 1999
8. Bostom AG, Shemin D, Verhoef P, et al: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vase Biol 17:2554-2558, 1997
9. Dierkes J, Domrose U, Westphal S, et al: Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 102:1946-1949, 2000
10. Arnadottir M, Hultberg B, Nilsson-Ehle P, et al: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56:41-46, 1996
11. House JD, Brosnan ME, Brosnan JT: Characterization of homocysteine metabolism in the rat kidney. Biochem J 328:287-292, 1997
12. Perna AF, Ingrosso D, De Santo NG, et al: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosyl-homocysteine in uremia. Kidney Int 47:247-253, 1995
13. Deutsche Gesellschaft für Ernährung: Empfehlungen für die Nährstoffzufuhr. Frankfurt/M (Germany), Umschau, 1991
14. Ubbink JB, Vermaak WJ, van der Merwe A, et al: The effect of blood sample aging and food consumption on plasma total homocysteine levels. Clin Chim Acta 207:119-128, 1992
15. Dierkes J, Kroesen M, Pietrzik K: Folic acid and Vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women. Int J Vitam Nutr Res 68:98-103, 1998
16. van Guldener C, Janssen MJ, Lambert J, et al: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 13:106-112, 1998
17. Ubbink JB, Vermaak WJ, van der Merwe A, et al: Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 124:1927-1933, 1994
18. Homocysteine Lowering Trialists' Collaboration: Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 316:894-898, 1998
19. Arnadottir M, Brattstrom L, Simonsen O, et al: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40:236-240, 1993
20. Janssen MJ, van Guldener C, de Jong GM, et al: Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 22:110-114, 1996
21. McGregor D, Shand B, Lynn K: A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron 85:215-220, 2000
22. Spence JD, Cordy P, Kortas C, et al: Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: No difference between 1 and 5 mg daily. Am J Nephrol 19:405-410, 1999
23. Sunder-Plassmann G, Fodinger M, Buchmayer H, et al: Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study. J Am Soc Nephrol 11:1106-1116, 2000
24. Bostom AG, Shemin D, Lapane KL, et al: High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
25. Touam M, Zingraff J, Jungers P, et al: Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 56:2292-2296, 1999
26. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 52:10-20, 1997
27. Beaulieu AJ, Gohh RY, Han H, et al: Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler Thromb Vase Biol 19: 2918-2921, 1999